Skip to content
  • Home
  • Signal News
  • Biopharma Digest
    • Market Access Intelligence
    • Rare Disease Gene Therapy
    • Oncology
  • Week in Review
    • GLP-1 Competitive Market
    • NeuroMarket Pulse
      • Neurology Regulatory Interactive Calendar
    • Manufacturing Intelligence
  • Contact

Pharminent

 Posted in Clinical Data

Viridian reports positive results from elegrobart phase 3 trial

 April 1, 2026

PharmaTimes

Company says treatment shows strong efficacy and convenient dosing profile

Clinical DataRead full story

Post navigation

ACC 2026: dulaglutide promotes coronary plaque stabilisation in patients with T2D →
← FDA approves new high dose Spinraza regimen for SMA

Categories

© 2026 Pharminent. All rights reserved.

Design by ThemesDNA.com